A recent post-hoc analysis of large-scale randomized controlled trials (RCTs), including the Canagliflozin Cardiovascular Assessment Study (CANVAS), African American Study of Kidney Disease and Hypertension (AASK), and Veterans Affairs Nephropathy in Diabetes trial (VA NEPHRON-D), demonstrated that changes in the TNFR levels also predict the eGFR decline, indicating the potential utility of TNFRs as alternatives to albuminuria as biomarkers in therapeutic monitoring and prognosis of CKD [27,28]. Here, TNFRSF1A is linked to chronic kidney disease.